1. Home
  2. OFS vs ANL Comparison

OFS vs ANL Comparison

Compare OFS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Capital Corporation

OFS

OFS Capital Corporation

HOLD

Current Price

$4.33

Market Cap

67.1M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.11

Market Cap

62.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFS
ANL
Founded
2001
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
62.0M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
OFS
ANL
Price
$4.33
$10.11
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
75.1K
1.0M
Earning Date
03-02-2026
02-24-2026
Dividend Yield
15.70%
N/A
EPS Growth
N/A
N/A
EPS
0.24
N/A
Revenue
$42,970,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.28
$0.88
52 Week High
$9.80
$12.09

Technical Indicators

Market Signals
Indicator
OFS
ANL
Relative Strength Index (RSI) 35.95 85.75
Support Level $4.91 $1.63
Resistance Level $5.01 $12.09
Average True Range (ATR) 0.25 1.39
MACD -0.07 0.81
Stochastic Oscillator 11.31 81.17

Price Performance

Historical Comparison
OFS
ANL

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: